ProKidney

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

- Company will present five posters discussing REACT and chronic kidney disease during the ASN Annual Meeting, November 3 - 6, 2022

ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2022

WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m. ET on Thursday, September 29, 2022, in New York, NY.

ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit

WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will participate in a fireside chat on Wednesday, September 14, 2022, at the Morgan Stanley 20 th Annual Global Healthcare Conference, in New York, NY. During the fireside chat, ProKidney plans to discuss its commercialization strategies and potential line extensions to expand market access, approaches to drive down cost of goods, and scaling of manufacturing to meet future market demand.

ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Brings nearly 20 years of investor relations and corporate communications experience to ProKidney

ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations

Completed business combination with Social Capital Suvretta Holdings, III Completed business combination with Social Capital Suvretta Holdings, III

ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidney Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidney

ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Social Capital Suvretta Holdings Corp I

WINSTON-SALEM, N,C. and PALO ALTO, Calif., July 12, 2022 (GLOBE NEWSWIRE) --  ProKidney LP (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on CKD, and Social Capital Suvretta Holdings Corp. III (“SCS”) (Nasdaq: DNAC), a special purpose acquisition company, today completed their previously announced business combination. The newly formed company is named ProKidney Corp. and its Class A ordinary shares will commence trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “PROK” on July 12, 2022.

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

News for ProKidney Stock (PROK)